Genetic basis and molecular profiling in myeloproliferative neoplasms
D Luque Paz, R Kralovics, RC Skoda - Blood, 2023 - ashpublications.org
Abstract BCR:: ABL1-negative myeloproliferative neoplasms (MPNs) are clonal diseases
originating from a single hematopoietic stem cell that cause excessive production of mature …
originating from a single hematopoietic stem cell that cause excessive production of mature …
Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms
Philadelphia-negative classical myeloproliferative neoplasms (MPNs) include polycythemia
vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The 2016 …
vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The 2016 …
Inflammatory pathophysiology as a contributor to myeloproliferative neoplasms
DAC Fisher, JS Fowles, A Zhou, ST Oh - Frontiers in immunology, 2021 - frontiersin.org
Myeloid neoplasms, including acute myeloid leukemia (AML), myeloproliferative neoplasms
(MPNs), and myelodysplastic syndromes (MDS), feature clonal dominance and remodeling …
(MPNs), and myelodysplastic syndromes (MDS), feature clonal dominance and remodeling …
Myeloproliferative neoplasm stem cells
AJ Mead, A Mullally - Blood, The Journal of the American …, 2017 - ashpublications.org
Myeloproliferative neoplasms (MPNs) arise in the hematopoietic stem cell (HSC)
compartment as a result of the acquisition of somatic mutations in a single HSC that provides …
compartment as a result of the acquisition of somatic mutations in a single HSC that provides …
Essential thrombocythemia treatment algorithm 2018
Current drug therapy for myeloproliferative neoplasms, including essential thrombocythemia
(ET) and polycythemia vera (PV), is neither curative nor has it been shown to prolong …
(ET) and polycythemia vera (PV), is neither curative nor has it been shown to prolong …
NCCN guidelines insights: myeloproliferative neoplasms, version 2.2018
Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the
hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential …
hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential …
Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFNα in myeloproliferative neoplasms
M Mosca, G Hermange, A Tisserand… - Blood, The Journal …, 2021 - ashpublications.org
Classical BCR-ABL–negative myeloproliferative neoplasms (MPNs) are clonal disorders of
hematopoietic stem cells (HSCs) caused mainly by recurrent mutations in genes encoding …
hematopoietic stem cells (HSCs) caused mainly by recurrent mutations in genes encoding …
Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone
JJ Kiladjian, S Giraudier, B Cassinat - Leukemia, 2016 - nature.com
Interferon alpha (IFN-α) has been used for over 30 years to treat myeloproliferative
neoplasms (MPNs). IFN-α was shown to induce clinical, hematological, molecular and …
neoplasms (MPNs). IFN-α was shown to induce clinical, hematological, molecular and …
Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial
L Masarova, KP Patel, KJ Newberry, J Cortes… - The Lancet …, 2017 - thelancet.com
Background Pegylated interferon alfa-2a is an immunomodulatory agent used to treat
polycythemia vera. The durability of responses and long-term safety of this drug in patients …
polycythemia vera. The durability of responses and long-term safety of this drug in patients …
Therapy for myeloproliferative neoplasms: when, which agent, and how?
HL Geyer, RA Mesa - Blood, The Journal of the American …, 2014 - ashpublications.org
Myeloproliferative neoplasms, including polycythemia vera (PV), essential thrombocythemia,
and myelofibrosis (MF)(both primary and secondary), are recognized for their burdensome …
and myelofibrosis (MF)(both primary and secondary), are recognized for their burdensome …